Dr. Prem N. Yadav
  Senior Scientist and Ramanujan Fellow
Pharmacology Division,
Central Drug Research Institute,
Lucknow-226 031 (U.P), India
 
 
Phone No. +91 9918001143
E-Mail

[email protected]
[email protected]

Academic Background

Ph.D., Immunopharmacology - 1997-2002 - Dept. of Immunology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, INDIA.
M. Sc., Biochemistry - 1994-1996 - Lucknow University, Lucknow, INDIA
 
Professional Experience
 
•
 Research Associate (2007-2011) - Dept. of Pharmacology, University of North Carolina, Chapel Hill, NC, USA
•
 Post-Doctoral Fellow (2003–2007) – Dept. of Biochemistry and Molecular Biology, New Jersey Medical School, UMDNJ, Newark, NJ, USA
 
Research Interest
 
•

Our overarching goal is to understand the mechanisms of GPCR modulation of cognition in psychiatric disorders such as schizophrenia, depression and drug addiction. Using cutting-edge neurogenetic tools (e.g., engineered receptor technology-Designer Receptor Exclusively Activated by Designer Drug: DREADD), our current research planes are aimed to investigate biochemical and neuronal mechanisms involved in cognitive abnormalities with long term aim to discover novel targets/approaches for the treatment of cognitive impairments that spans across all CNS disorders. Another major focus of lab is to discover highly selective and brain penetrable and bioavailable Novel Chemical Entity (NCEs) that activates or inhibits GPCR targets using high throughput screening system, further develop them as therapeutics for the treatment of various CNS and cardiovascular diseases.

Selected Publications (last 5 year only)
 
•
 Dogra S and Yadav PN. 2015. Biased Agonism at Kappa Opioid Receptors: Implication in Pain and Mood Disorders. Eur. J. Pharmacol. 15;763(Pt B):184-90.)
•
 Singh N, Yadav M, Singh AK, Kumar H, Dwivedi SK, Mishra JS, Gurjar A, Manhas A, Chandra S, Yadav PN, Jagavelu K, Siddiqi MI, Trivedi AK, Chattopadhyay N, Sanyal S. 2014. Synthetic FXR agonist GW4064 is a modulator of multiple G-protein coupled receptors Mol Endocrinol. 28(5):659-73.
•
 Goldsmith JR, Perez-Chanona E, Yadav PN, Whistler JL, Roth BL, Jobin C. 2013. Intestinal epithelial cell (IEC)-derived mu-opioid signaling is protective against ischemia reperfusion (I/R) induced injury. Am J Pathol. 182(3):776-85.
•
 Farrell MS, Pei Y, Wan Y, Yadav PN, Daigle TL, Setola V, Sciaky N, Simmons A, Nonneman RJ, Huang XP, Hufeisen SJ, Guettier JM, Moy SS,Wess J, Caron MG, Calakos N, Roth BL. 2013. A Gαs DREADD mouse for selective modulation of cAMP production in striatopallidal neurons. Neuropsychopharmacology. 38(5):854-62.
•
 Yadav PN, Kroeze WK, Farrell MS, Roth BL. 2012 Antagonist functional selectivity: 5-HT2A serotonin receptor antagonists differentially regulate 5-HT2A receptor protein level in vivo. J Pharmacol Exp Ther.;339 (1):99-105.
•
 Allen JA, Yost JM, Setola V, Chen X, Sassano MF, Chen M, Peterson S, Yadav PN, Huang XP, Feng B, Jensen NH, Che X, Bai X, Frye SV, Wetsel WC, Caron MG, Javitch JA, Roth BL, Jin J. 2011. Discovery of Beta -Arrestin-Biased Dopamine D2 Ligands as Chemical Tools for Probing Signal Transduction Pathways Essential for Antipsychotic Efficacy. Proc. Natl. Acad. Sci. USA 108(45):18488-93.
•
 Yadav PN, Abbas AI, Farrell MS, Setola V, Sciaky N, Huang XP, Kroeze WK, Crawford LK, Piel DA, Keiser MJ, Irwin JJ, Shoichet BK, Deneris ES, Gingrich J, Beck SG, Roth BL. 2010. The Presynaptic component of the serotonergic system is required for clozapine's efficacy. Neuropsychopharmacology.
•
 Magalhaes AC, Dale LB, Holmes KD, Comps-Agrar L, Lee D, Yadav PN, Poulter MO, Roth BL, Pin J, Anisman H, and Ferguson SSG. 2010. CRF receptor1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling. Nature Neurosci. 13:622-9.